Pralatrexate

From WikiMD's Wellnesspedia

What is Pralatrexate?[edit | edit source]

Pralatrexate
Pralatrexate ball-and-stick



What are the uses of this medicine?[edit | edit source]

  • Pralatrexate (Folotyn) is a prescription anti-cancer (chemotherapy) medicine. Folotyn is used to treat people with a type of cancer called Peripheral T-cell Lymphoma (PTCL) that does not go away, gets worse, or comes back after use of another cancer treatment.

PTCL:


How does this medicine work?[edit | edit source]

  • Pralatrexate (pral" a trex' ate) is a folate analogue which acts as an antagonist to the enzymes involved in folate dependent synthetic pathways such as thymidine synthase, dihydrofolate reductase and glycinamide ribonucleotide formyltransferase.
  • Inhibition of these enzymes leads to decrease in intracellular concentrations of thymidine and purine which blocks RNA and DNA synthesis and leads to apoptotic cell death in rapidly dividing cells.
  • In vitro and in vivo studies have shown that pralatrexate has activity against peripheral T cell lymphomas.


Who Should Not Use this medicine ?[edit | edit source]

  • This medicine have no usage limitations.


What drug interactions can this medicine cause?[edit | edit source]

  • Some medicines may affect how Folotyn works, and Folotyn may affect how other medicines work.

Especially tell your doctor if you take:


Is this medicine FDA approved?[edit | edit source]


How should this medicine be used?[edit | edit source]

  • Prior to initiating Folotyn, supplement patients with vitamin B12 1 mg intramuscularly every 8-10 weeks and folic acid 1.0-1.25 mg orally on a daily basis.

Recommended dosage:

  • The recommended dose of Folotyn is 30 mg/m2 administered as an intravenous push over 3 to 5 minutes once weekly for 6 weeks in 7-week cycles.
  • For patients with severe renal impairment (eGFR 15 to < 30 mL/min/1.73 m2), the recommended dose of Folotyn is 15 mg/m2.
  • Management of severe or intolerable adverse reactions may require dose omission, reduction, or discontinuation of Folotyn therapy.


Administration:

  • Folotyn will be given to you as directed by your doctor, as an intravenous (IV) injection into your vein over 3 to 5 minutes.
  • Folotyn is usually given in cycles, one time each week for 6 weeks, with no treatment on the 7th week. Treatment with Folotyn may be continued as long as it is helpful to you.
  • To lower your chances of harmful side effects, it is important that you take folic acid and vitamin B12 during your treatment with Folotyn. Your doctor will give you specific instructions for vitamin supplementation.
  • You will take folic acid by mouth for 10 days before your first dose of Folotyn. Do not take more or less folic acid than your doctor tells you to take. Continue taking folic acid every day until your doctor tells you to stop.
  • Your doctor will give you a vitamin B12 injection into your muscle (intramuscular) before your first dose of Folotyn and about every 8 to 10 weeks during treatment with Folotyn.
  • You should have regular blood tests before and during your treatment with Folotyn. Your doctor may change your dose of Folotyn or delay treatment based on the results of your blood tests and on your general condition.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As Sterile, single-dose vials containing pralatrexate at a concentration of 20 mg/mL in the following presentations:
  • 20 mg of pralatrexate in 1 mL solution in a vial (20 mg / 1 mL)
  • 40 mg of pralatrexate in 2 mL solution in a vial (40 mg / 2 mL)


This medicine is available in fallowing brand namesː

  • Folotyn


What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:

Folotyn may cause serious side effects, including:


What special precautions should I follow?[edit | edit source]

  • Folotyn can cause bone marrow suppression, manifested by thrombocytopenia, neutropenia, and/or anemia. Monitor blood counts and omit and/or reduce dose for hematologic toxicities.
  • Folotyn can cause mucositis. Monitor at least weekly. If ≥ Grade 2 mucositis is observed, omit and/or reduce dose.
  • Folotyn can cause severe dermatologic reactions, which may result in death. Reactions, including fatal reactions, have occurred and may be progressive and increase in severity with further treatment. Monitor closely, and omit and/or reduce dose or discontinue Folotyn.
  • Folotyn can cause tumor lysis syndrome (TLS). Monitor patients who are at increased risk of TLS and treat promptly.
  • Folotyn can cause hepatic toxicity and liver function test abnormalities. Monitor for toxicity. For liver function test abnormalities Grade 3 or greater, omit until recovery then reduce dose or discontinue therapy as required.
  • Patients with moderate to severe renal function impairment may be at greater risk for increased exposure and toxicity. Monitor patients for renal function and systemic toxicity and adjust dosing accordingly. Avoid Folotyn use in patients with end stage renal disease including those undergoing dialysis unless the potential benefit justifies the potential risk.
  • Folotyn can cause fetal harm when administered to a pregnant woman. Women should avoid becoming pregnant while being treated with Folotyn. Inform pregnant women of the potential harm to the fetus.


What to do in case of emergency/overdose?[edit | edit source]

Symptoms of overdosage may include:

  • No specific information is available on overdosage of Folotyn.

Management of overdosage:

  • If an overdose occurs, general supportive measures should be instituted as deemed necessary by the treating physician.
  • Based on Folotyn's mechanism of action, consider the prompt administration of leucovorin.


Can this medicine be used in pregnancy?[edit | edit source]

  • Folotyn can cause fetal harm when administered to a pregnant woman.
  • If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.


Can this medicine be used in children?[edit | edit source]

  • The safety and effectiveness of Folotyn in pediatric patients have not been established.


What are the active and inactive ingredients in this medicine?[edit | edit source]

  • Active ingredient: pralatrexate
  • Inactive ingredients: sodium chloride, sodium hydroxide, and hydrochloric acid


Who manufactures and distributes this medicine?[edit | edit source]

Manufactured for:


What should I know about storage and disposal of this medication?[edit | edit source]

  • Vials must be stored refrigerated at 2-8°C (36-46°F) in original carton to protect from light.
  • Handle and dispose of Folotyn according to guidelines issued for cytotoxic drugs, including the use of gloves and other protective clothing to prevent skin contact.
  • Each vial of Folotyn is intended for single use only. Any unused drug remaining after injection must be discarded.


Alphabetic list of antineoplastic agents - 0-9 - A1 - A2 - A3 - A4 - A5 -A6 - B - C - D - E - F - G - H - I - JK - L - M - NO - PQ - R - S - T - UVW - XYZ


Pralatrexate Resources

Find a healthcare provider anywhere in the world quickly and easily!

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski

WikiMD.png


WikiMD is the world's largest, free medical and wellness encyclopedia edited only by professionals. Advertise!

Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.